Treat early with VABYSMO for rapid vision gains and extended durability over 2 years*¹

*Median of 3 injections between Week 60 and 96 for patients in VABYSMO 6.0 mg up to Q16W arm and a median of 5 injections between Week 60 and 96 for patients in VABYSMO 6.0 mg Q8W and aflibercept 2.0 mg Q8W arms. Based on study design; aflibercept 2.0 mg was not allowed to extend beyond Q8W dosing. †Aflibercept 2.0 mg Q8W initial dosing was 5 x monthly. VABYSMO 6.0 mg Q8W initial dosing was 6 x monthly. ‡Adjusted mean BCVA change from baseline, averaged over Week 92, 96 and 100. ^¶VABYSMO dosed up to Q16W met the primary endpoint, demonstrating noninferior vision gains vs aflibercept 2.0 mg Q8W, averaged over Week 48, 52 and 56 in both YOSEMITE and RHINE.⁵

VABYSMO delivers faster* drying with fewer* injections vs. aflibercept³

*Based on post hoc, exploratory analysis with nominal P-value statistical analysis not adjusted for multiple testing (nominal P-value <0.05 vs. aflibercept 2.0 mg Q8W), no formal statistical conclusions can be drawn. Primary endpoint of Phase III studies was non-inferiority in BCVA vs. aflibercept 2.0 mg Q8W for nAMD and DME, and aflibercept 2.0 mg Q4W for RVO. †Summaries of time to first absence of IRF are Kaplan-Meier estimates. ‡The number of injections includes any active drug administered (VABYSMO or aflibercept), including medication errors. §HR:1.67. Stratified analyses for HR and log-rank test. Stratification factors are baseline BCVA, prior intravitreal anti-VEGF therapy, region and study. HRs were estimated by Cox regression. Statistics for pairwise comparisons were calculated using a separate model for each comparison. HRs were estimated by Cox regression.

Greater* CST reductions with VABYSMO vs. aflibercept in the head-to-head matched dose phase, Year 1 and Year 2¹
 

*Based on post hoc, exploratory analysis with nominal P-value statistical analysis not adjusted for multiple testing (nominal P-value <0.05 vs. aflibercept 2.0 mg Q8W), no formal statistical conclusions can be drawn. Primary endpoint of Phase III studies was non-inferiority in BCVA vs. aflibercept 2.0 mg Q8W for nAMD and DME, and aflibercept 2.0 mg Q4W for RVO. †Nominal P<0.05 vs aflibercept 2.0 mg Q8W for change from baseline averaged over Week 48, 52 and 56. ‡Aflibercept 2.0 mg Q8W initial dosing was 5 x monthly. VABYSMO 6.0 mg Q8W initial dosing was 6 x monthly. VABYSMO 6.0 mg up to Q16W initial dosing was ≥4 x monthly. §Nominal P-value vs aflibercept 2.0 mg Q8W for change from baseline at Week 16. Nominal P<0.05 vs aflibercept 2.0 mg Q8W for change from baseline over Week 92, 96 and 100. Results are based on a mixed model for repeated measures analysis. **Median of 3 injections between Week 60 and 96 for patients in the VABYSMO 6.0 mg up to Q16W arm and a median of 5 injections between Week 60 and 96 for patients in the VABYSMO 6.0 mg Q8W arm and aflibercept 2.0 mg Q8W arm. Based on study design; aflibercept 2.0 mg was not allowed to extend beyond Q8W dosing.

More* patients achieve IRF resolution with VABYSMO vs. aflibercept over 2 years^1,4
 

*Based on post hoc, exploratory analysis with nominal P-value statistical analysis not adjusted for multiple testing (nominal P-value <0.05 vs. aflibercept 2.0 mg Q8W), no formal statistical conclusions can be drawn. Primary endpoint of Phase III studies was non-inferiority in BCVA vs. aflibercept 2.0 mg Q8W for nAMD and DME, and aflibercept 2.0 mg Q4W for RVO. 

VABYSMO delivers extended durability with ~80% of patients on Q12W or Q16W treatment intervals at Year 2¹
 

*Primary endpoint of Phase III studies was non-inferiority in BCVA vs. aflibercept 2.0 mg Q8W for nAMD and DME, and aflibercept 2.0 mg Q4W for RVO. Patients with evaluable data at Week 96 in the VABYSMO 6.0 mg up to Q16W arm. †During Week 60 to Week 96. 

VABYSMO has a favourable benefit-risk profile demonstrated in 6 Phase III trials and in real-world settings*^1,5–7
 

*As of January 2024, >3 million doses have been distributed worldwide.⁸ †No comparison possible for Week 24 to Week 72 RVO data (BALATON/COMINO). ‡An external review of investigator reported IOI cases reported in Phase III trials found no patterns suggestive of IOI related occlusive retinal vasculitis.